Abstract

Disulfidptosis regulate various biological processes in cancer. However, there is limited research on the genes related to disulfidptosis in predicting the prognosis of hepatocellular carcinoma (HCC). We aimed to develop a reliable disulfidptosis-related gene signature, which will characterize different HCC subtypes and predict their prognosis. The Cancer Genome Atlas (TCGA)-HCC dataset, comprising RNA sequencing data and clinical information, was obtained from the TCGA database. The crucial disulfidptosis-related genes were selected for bioinformatic analysis in HCC. HCC tumor classification was established through a consistent cluster analysis. The prognosis and immune-cell infiltration were investigated in association with a disulfidptosis-related HCC model. In TCGA-HCC patients, a total of 3,621 prognostic genes and 30 key prognostic disulfidptosis-related genes were identified. Using key prognostic disulfidptosis-related genes, TCGA-HCC patients were categorized into low- and high-risk clusters. The upregulated differentially expressed genes (DEGs) in high-risk cluster 1 (C1) could significantly impact cell cycle, DNA replication, and the p53 signaling pathway, whereas the pathways associated with the downregulated DEGs in high-risk C1 could significantly impact metabolism of xenobiotics by cytochrome P450, the PPAR signaling pathway, and tyrosine metabolism. Furthermore, the immune activity of the high-risk C1 group was different to that of the low-risk cluster 2 (C2) group. The 13 disulfidptosis-related genes were finally screened using least absolute shrinkage and selection operator (LASSO) regression analysis, including ANP32E, BOP1, RPN1, SLC7A11, PPIH, PCBP2, ME1, PRDX1, FLNC, INF2, MYH11, LRPPRC, and HNRNPM. The genes related to disulfidptosis are closely associated with tumor classification and immunity in patients with HCC. This is the first gene signature related to disulfidptosis demonstrated a strong predictive performance for the prognosis of HCC, which provide new perspectives for the diagnosis and treatment of HCC.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.